Celgene stock has formed a great looking consolidation or basing pattern after dropping -35% on news that was not too bad. I think we have a great bottom feeder play here.
While Bluebird Bio stock doesn't look like a good entry right now, they are advancing a CAR T treatment that looks extremely promising.
Sorrento Therapeutics Inc has bounced off its 61.8 percent Fibonacci retracement level. Sorrento Therapeutics had a decline in short interest in the month of September. As of September 29th, there
CAR T stocks are the buzz right now. Even grocery store workers are talking about the FDA approval of the first CAR-T therapy from Novartis last week. Labiotech wrote about
The Cellectis CAR T treatment will be better than Novartis on price point. The Novartis therapy called tisagenlecleucel will be very expensive and this is a big problem as insurance
Big news: Novartis FDA Car T approval is likely coming soon after a Food and Drug Administration advisory panel unanimously recommended approval for Novartis's leukemia drug tisagenlecleucel. The FDA usually
The European Medicines Agency gave an update on the various T-cell therapies progressing through clinical trials across Europe. The video below is very important for those of us who trade
Glioblastoma is a malignant and rapidly growing astrocytoma of the central nervous system and usually is detected in the brain. Glioblastoma is the worst grade of malignant glioma, a relatively